Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Sort by Random

Display 15 Products per page

Aggrenox
Read More
Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole.
July 2, 2018
Find out more
Cymbalta
Read More
Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia in the US, and most recently, chronic musculoskeletal pain.
March 29, 2019
Find out more
Gralise
Read More
Gralise (gabapentin; Depomed) is an extended-release formulation of gabapentin, an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and is used for treatment of restless leg syndrome and post-herpetic neuralgia (PHN).
May 31, 2018
Find out more
Gleevec
Read More
Gleevec (imatinib; Novartis) is an orally administered BCR-ABL tyrosine kinase inhibitor (TKI). The BCR-ABL fusion gene activates a number of signaling pathways that facilitate cancer cell transformation and proliferation.
December 7, 2017
Find out more
Adcirca
Read More
Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).
October 29, 2018
Find out more
Plavix
Read More
Plavix is an antiplatelet agent that inhibits blood clot formation. It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex.
July 2, 2018
Find out more
Yescarta
Read More
Yescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained US approval for relapsed/refractory patients in October 2017.
January 30, 2019
Find out more
Lantus
Read More
Lantus (insulin glargine; Sanofi) was the first long-acting basal insulin analog to reach the market.
November 7, 2017
Find out more
Tygacil
Read More
Tygacil (tigecycline; Pfizer) is the first of the glycylcycline class of antimicrobial agents. It targets and binds to the 30S subunit of the bacterial ribosomes.
June 19, 2015
Find out more
VB-111
Read More
VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin

(bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data

from the Phase III GLOBE study.
April 13, 2016
Find out more
Dovobet
Read More
Leo Pharma developed and launched Dovobet (also known as Daivobet, Taclonex, Xamiol, and LEO-80185), a dermatological ointment formulation of the vitamin D analog calcipotriol and the corticosteroid betamethasone dipropionate, for the treatment of…
August 28, 2016
Find out more
Betrixaban
Read More
Betrixaban (Portola Pharmaceuticals) is an oral, once-daily inhibitor of factor Xa that catalyzes conversion of prothrombin to thrombin, preventing thrombosis. Betrixaban is currently in Phase III development…
August 2, 2016
Find out more
Talzenna
Read More
Talzenna (talazoparib; Pfizer) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events, by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
February 26, 2020
Find out more
Viibryd
Read More
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect.
March 29, 2019
Find out more
ProstAtak
Read More
ProstAtak (AdV-tk + valacyclovir) is a viral cancer vaccine being developed by Advantagene for the treatment of prostate cancer. It works by gene-mediated cytotoxic immunotherapy, an approach that generates a tumor-specific vaccine.
September 24, 2015
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *